scholarly journals 3O Identification of an endogenous retroviral signature to predict PD-1 blockade response in advanced clear cell renal cell carcinoma: Integrated analysis of three clinical trials

2021 ◽  
Vol 32 ◽  
pp. S1375
Author(s):  
J-G. Zhou ◽  
H. Wang ◽  
H. Ma ◽  
U.S. Gaipl
2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
A Ari Hakimi ◽  
Anders Jacobsen ◽  
Roy Mano ◽  
Mithat Gonen ◽  
Martin H. Voss ◽  
...  

Lab on a Chip ◽  
2020 ◽  
Vol 20 (23) ◽  
pp. 4420-4432
Author(s):  
María Virumbrales-Muñoz ◽  
Jiong Chen ◽  
Jose Ayuso ◽  
Moonhee Lee ◽  
E. Jason Abel ◽  
...  

Identification and testing of personalized anti-angiogenic treatments for clear cell renal cell carcinoma using patient-derived microfluidic models of normal and tumor-associated blood vessels.


2017 ◽  
Vol 15 (6) ◽  
pp. 652-660.e1 ◽  
Author(s):  
Guillermo de Velasco ◽  
Rana R. McKay ◽  
Xun Lin ◽  
Raphel B. Moreira ◽  
Ronit Simantov ◽  
...  

2020 ◽  
Vol 7 (9) ◽  
pp. 1446
Author(s):  
Soumish Sengupta ◽  
Supriya Basu ◽  
Kadambari Ghosh

Non-clear cell renal cell carcinoma (nccRCC) is not as common as clear cell renal cell carcinoma (ccRcc). But then it is not uncommon in regular urological practice. It usually carries a grave prognosis. Authors need to converse ourselves with National comprehensive cancer network (NCCN) categories for evidence and we need to converse as well with NCCN categories for preferences. ‘Preferred intervention’ is based on superior efficacy, safety and evidence and when appropriate, affordability. ‘Other recommended interventions’ are somewhat less efficacious, more toxic, or based on less mature data or significantly less affordable for similar outcomes. ‘Useful in certain circumstances’ are interventions that may be used for a selected patient population. Clinical trials for targeted agents are mainly directed at ccRCC because of its high prevalence. According to the NCCN panel, enrolment in clinical trials is the preferred strategy for nccRCC. Outcomes of patients with nccRCC have improved with the introduction of targeted therapy. Precise pathological diagnosis of the types of nccRCC by immunohistochemical analysis is mandatory. This enables specific treatments for individual nccRCC. Currently TKIs are the drug of choice (both first and second line) for metastatic papillary RCC. Both TKIs and mTOR inhibitors are effective against chromophobe RCC. Platinum based chemotherapy should be used for metastatic CDC. Further evidence is required for management of nccRCC. 


2021 ◽  
Vol 2021 ◽  
pp. 1-35
Author(s):  
Yue Wu ◽  
Xian Wei ◽  
Huan Feng ◽  
Bintao Hu ◽  
Bo Liu ◽  
...  

The imbalance of the redox system has been shown to be closely related to the occurrence and progression of many cancers. However, the biological function and clinical significance of redox-related genes (RRGs) in clear cell renal cell carcinoma (ccRCC) are unclear. In our current study, we downloaded transcriptome data from The Cancer Genome Atlas (TCGA) database of ccRCC patients and identified the differential expression of RRGs in tumor and normal kidney tissues. Then, we identified a total of 344 differentially expressed RRGs, including 234 upregulated and 110 downregulated RRGs. Fourteen prognosis-related RRGs (ADAM8, CGN, EIF4EBP1, FOXM1, G6PC, HAMP, HTR2C, ITIH4, LTB4R, MMP3, PLG, PRKCG, SAA1, and VWF) were selected out, and a prognosis-related signature was constructed based on these RRGs. Survival analysis showed that overall survival was lower in the high-risk group than in the low-risk group. The area under the receiver operating characteristic curve of the risk score signature was 0.728 at three years and 0.759 at five years in the TCGA cohort and 0.804 at three years and 0.829 at five years in the E-MTAB-1980 cohort, showing good predictive performance. In addition, we explored the regulatory relationships of these RRGs with upstream miRNA, their biological functions and molecular mechanisms, and their relationship with immune cell infiltration. We also established a nomogram based on these prognostic RRGs and performed internal and external validation in the TCGA and E-MTAB-1980 cohorts, respectively, showing an accurate prediction of ccRCC prognosis. Moreover, a stratified analysis showed a significant correlation between the prognostic signature and ccRCC progression.


2005 ◽  
Vol 174 (5) ◽  
pp. 1759-1763 ◽  
Author(s):  
BRADLEY C. LEIBOVICH ◽  
JOHN C. CHEVILLE ◽  
CHRISTINE M. LOHSE ◽  
HORST ZINCKE ◽  
IGOR FRANK ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document